Not everyone is a candidate for Tirzepatide
Noom first launched its GLP-1 Companion in November 2023 and has continued to invest heavily in the program since launch, adding features like Muscle Defense, AI food logging, medication tracking and side effect support, AI-powered body composition scans, glucose curve forecasting, stress-relief activities, and gamification of healthy behaviors like achieving step goals and eating healthy snacks
Including dopaminergic reward pathways, hippocampal neurogenic zones, prefrontal cortex, and neuroinflammatory microglia , and Semaglutides central nervous system biology has expanded into neurological research applications including addiction biology, neurodegeneration, Parkinsons disease neuroinflammation, and Alzheimers disease amyloid biology
[19] It has been available as a generic medication in the United States since 2004